| 6.26 Delayed Data As of 2:41pm ET |  -0.29 / -4.43%Today’s Change | 4.01 Today|||52-Week Range 51.60 | -82.99% Year-to-Date |
| Are Options Traders Betting on a Big Move in Novavax (NVAX) Stock? Sep 17 / Zacks.com - Paid Partner Content |
| Previous close | 6.55 |
| Today’s open | 6.56 |
| Day’s range | 6.20 - 6.63 |
| Volume | 347,565 |
| Average volume (3 months) | 881,135 |
| Market cap | $156.9M |
| Earnings growth (last year) | +20.69% |
| Earnings growth (this year) | +45.10% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | +9.98% |
| P/E ratio | NM |
| Price/Sales | 19.84 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| LCTXLineage Cell Therape... | -0.01 | -0.93% |
| TLCTaiwan Liposome Co L... | +0.15 | +2.90% |
| ALDXAldeyra Therapeutics... | -0.04 | -0.59% |
| DYAIDyadic International... | +0.27 | +4.40% |
| Next reporting date | November 7, 2019 |
| EPS forecast (this quarter) | -$0.88 |
| Annual revenue (last year) | $34.3M |
| Annual profit (last year) | -$184.7M |
| Net profit margin | -538.81% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Stanley C. Erck |
CFO, Treasurer, Chief Business Officer & Senior VP John J. Trizzino |
Corporate headquarters Gaithersburg, Maryland |
